These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12546642)

  • 1. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.
    Dockery F; Bulpitt CJ; Agarwal S; Donaldson M; Rajkumar C
    Clin Sci (Lond); 2003 Feb; 104(2):195-201. PubMed ID: 12546642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness.
    Dockery F; Bulpitt CJ; Agarwal S; Rajkumar C
    Aging Male; 2002 Dec; 5(4):216-22. PubMed ID: 12630068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer.
    Dockery F; Bulpitt CJ; Agarwal S; Vernon C; Rajkumar C
    J Androl; 2009; 30(4):410-5. PubMed ID: 19168445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer.
    Xu T; Wang X; Hou S; Zhu J; Zhang X; Huang X
    Chin Med J (Engl); 2002 Sep; 115(9):1336-40. PubMed ID: 12411107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
    Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
    J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.
    Dockery F; Bulpitt CJ; Agarwal S; Vernon C; Nihoyannopoulos P; Kemp M; Hooper J; Rajkumar C
    Clin Endocrinol (Oxf); 2008 Jan; 68(1):59-65. PubMed ID: 17692108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between low serum endogenous androgen concentrations and arterial stiffness in men with type 2 diabetes mellitus.
    Fukui M; Ose H; Kitagawa Y; Yamazaki M; Hasegawa G; Yoshikawa T; Nakamura N
    Metabolism; 2007 Sep; 56(9):1167-73. PubMed ID: 17697857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary report: the effect of a 6-month dietary glycemic index manipulation in addition to healthy eating advice and weight loss on arterial compliance and 24-hour ambulatory blood pressure in men: a pilot study.
    Philippou E; Bovill-Taylor C; Rajkumar C; Vampa ML; Ntatsaki E; Brynes AE; Hickson M; Frost GS
    Metabolism; 2009 Dec; 58(12):1703-8. PubMed ID: 19604522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW; Clarke HS; Hancock WC; Keane TE
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    J Urol; 2011 Oct; 186(4):1291-7. PubMed ID: 21849187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and gender related patterns in carotid-femoral PWV and carotid and femoral stiffness in a large healthy, middle-aged population.
    Vermeersch SJ; Rietzschel ER; De Buyzere ML; De Bacquer D; De Backer G; Van Bortel LM; Gillebert TC; Verdonck PR; Segers P
    J Hypertens; 2008 Jul; 26(7):1411-9. PubMed ID: 18551018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.